Stockscreener 앱 받기
33.92
5.21%
1.68
시간 외 거래:
33.91
-0.01
-0.03%
Vtv Therapeutics Inc 주식(VTVT)의 최신 뉴스
VTVT Q1 2026 Earnings: Surprise Profit Amid No RevenueEarnings Preview - newsline.com
Price-Driven Insight from (VTVT) for Rule-Based Strategy - Stock Traders Daily
vTv Therapeutics, Inc. Class A Financial Disclosures & SEC Filings - TradingView
VTVT Q1 2026 Earnings: Massive EPS Beat Driven by Non-Operational ItemsForward EPS Estimate - newsline.com
VTVT Technical Analysis | Trend, Signals & Chart Patterns | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
Stock options, 10-year term: inside vTv Therapeutics grant - Stock Titan
VTVT Stock Price, Quote & Chart | VTV THERAPEUTICS INC- CL A (NASDAQ:VTVT) - ChartMill
MSN Money - MSN
vTv Therapeutics Drops as Diabetes Study Date Approaches - Bez Kabli
vTv Therapeutics (VTVT) Edges Lower, Holding Above Key Support Amid ConsolidationRisk Parity Rebalance - thelegaladvocate.com
(VTVT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
VTVT Q1 2026 Earnings: Massive EPS Surprise Driven by a Non-Recurring GainEarnings Quality Score - The Legal Advocate
VTVT Q1 2026 Earnings: Massive EPS Beat Driven by One-Time Items, Stock DeclinesCEO Earnings Statement - The Legal Advocate
vTv Therapeutics Inc. (VTVT) Slips 3% as Resistance Holds; Traders Eye Support TestLow Beta Factor - newsline.com
vTv Therapeutics Q1 2026 Earnings: Massive EPS Surprise on One-Time Gains, Shares SlipProfit Margin Analysis - newsline.com
vTv Therapeutics Inc. Q1 2026 Earnings: Massive EPS Surprise Amid Revenue Shortfall and Stock DeclineEBITDA Estimate Trend - The Legal Advocate
vTv Therapeutics Inc. (VTVT) Q1 2026 Earnings: Massive EPS Surprise Despite No RevenueAnalyst Stock Picks - Newser
VTVT | vTv Therapeutics Inc. Class Insider Trading - Quiver Quantitative
vTv Therapeutics Inc. (NASDAQ:VTVT) Just Beat Earnings: Here's What Analysts Think Will Happen Next - Yahoo Finance
(VTVT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
vTv Therapeutics (VTVT) Q1 2026 Earnings: EPS $1.65 Beats EstimatesRevenue Report - newser.com
vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance
TD Cowen Maintains VTv Therapeutics(VTVT.US) With Buy Rating, Maintains Target Price $67 - Moomoo
Analyst Maintains Buy on vTv Therapeutics, Reiterates Unchanged $49 Price Target Amid Progress of Cadisegliatin Program - TipRanks
H.C. Wainwright cuts vTv Therapeutics stock price target to $45 By Investing.com - Investing.com Nigeria
H.C. Wainwright cuts vTv Therapeutics stock price target to $45 - Investing.com
vTv Therapeutics Inc. Files Form 8-K for Class A Common Stock on Nasdaq – Company Information and SEC Filing Details - Minichart
vTv Therapeutics (VTVT) Reports Strong Q1 Revenue and Trial Prog - GuruFocus
Is vTv Therapeutics (VTVT) 322.2% Overvalued After Q1 2026? EPS - GuruFocus
vTv Therapeutics Expands At-The-Market Share Program Capacity - TipRanks
Recent filings by vTv Therapeutics Inc. to the U.S. Securities and Exchange Commission (SEC) show that the company has increased its allocation of Class A common shares issued under the at-the-market offering (ATM) plan to the full amount. - Bitget
vTv Therapeutics (NASDAQ: VTVT) registers $47.5M ATM to fund cadisegliatin - Stock Titan
vTv Therapeutics (VTVT) expands ATM share offering, files Dechert legal opinion - Stock Titan
vTv Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
vTv Therapeutics Inc. 1Q 2026: Revenue $36.8M, Net income $24.1M — 10-Q Summary - TradingView
Licensing windfall lifts vTv Therapeutics (NASDAQ: VTVT) to Q1 2026 profit and stronger cash - Stock Titan
[8-K] vTv Therapeutics Inc. Reports Material Event - Stock Titan
vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
VTv Therapeutics: Q1 Earnings Snapshot - kare11.com
Oral type 1 diabetes drug advances: vTv expects cash through Phase 3 data - Stock Titan
VTv Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
TradingKey - TradingKey
vTv Therapeutics (VTVT) Projected to Post Earnings on Wednesday - MarketBeat
vTv Therapeutics Inc. (NASDAQ:VTVT) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
2.60%
0.94%
자본화:
|
볼륨(24시간):